BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 million

17d ago, source:

With $200 million and three drugs in or near clinical trials, a spinout of BridgeBio Pharma Inc. aims to flip the switch on a ...

BridgeBio Pharma's Options: A Look at What the Big Money is Thinking

3d ago, source:

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $1,085,600, and 6 are calls, amounting to ...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4d ago, source:

PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma, Inc. (BBIO)

2d ago, source: Yahoo Finance

PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

There Is Nothing Like BridgeBio Pharma Inc (BBIO) Stock

3d ago, source: bovnews

Raymond James raised the price target for the BridgeBio Pharma Inc (NASDAQ:BBIO) stock to “an Outperform”. The rating was released on March 21, 2024, according to finviz. The research report from ...

Promising Clinical Data Bolsters Buy Rating for BridgeBio Pharma

3d ago, source: Business Insider

Begin your TipRanks Premium journey today. BridgeBio Pharma (BBIO) Company Description: BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from ...

Buy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive Edge

3d ago, source:

Jason Zemansky, an analyst from Bank of America Securities, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The ...

BridgeBio Pharma: Q1 Earnings Snapshot

17d ago, source: The Washington Post

PALO ALTO, Calif. — PALO ALTO, Calif. — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $35.2 million in its first quarter. The Palo Alto, California-based company said it had a ...

BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 million

17d ago, source: The Business Journals

The move should allow BridgeBio Pharma to concentrate on its heart failure drug, which could win FDA approval in November, as the spinout's cancer drugs enter clinical trials. With $200 million ...

BridgeBio Pharma Inc BBIO

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Pharma Inc BBIO

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...